AbbVie (ABBV) just picked up two FDA Breakthrough Therapy Designations for its investigational cancer drug telisotuzumab adizutecan in colorectal and non small cell lung cancer, sharpening investor focus on the stock’s oncology pipeline.
That FDA news dropped into an already strong run for AbbVie. The stock has a 7.5% 30 day share price return and a 20.6% year to date share price gain. The 5 year total shareholder return of about 200% suggests momentum has been sustained over multiple cycles.
Scan AbbVie’s oncology catalyst alongside a curated set of potential peers and future winners in our 34 healthcare AI stocks.
AbbVie clearly has momentum in the lab and on the chart. The harder question now is whether a US$276 share price already reflects that strength or still leaves genuine value on the table.
Most Popular Narrative: 1% Undervalued
On the most followed view of AbbVie, a fair value of $278.61 sits just above the latest close at $276.47. This keeps attention firmly on whether pipeline execution can bridge that small gap over time.
The key requirement for AbbVie is successfully executing on its pipeline and business development so that new immunology, oncology and neuroscience drugs replace revenue from declining products such as Humira and Imbruvica.
Ongoing post Humira diversification, where management reports that Humira erosion of about US$18b has been offset by roughly US$28b of growth from other platforms and that 2026 guidance is almost US$10b above the pre Humira peak, reinforces the case that newer franchises can keep supporting overall revenue and adjusted EPS.
See why 326 investors see AbbVie as 1% undervalued.
Result: Fair Value of $278.61 (UNDERVALUED)
Still, AbbVie’s story can change quickly if pricing pressure on key therapies or faster than expected biosimilar competition eats into the earnings trajectory underpinning that 1% gap.
Find out about the key risks to this AbbVie narrative.
Another View: AbbVie On Earnings Multiples
Zoom out from fair value models and AbbVie looks expensive on a simple earnings yardstick. The stock trades on a P/E of 77.9x, compared with a fair ratio of 46.3x, the US Biotechs industry at 17.5x and peer average of 28x. That kind of gap can mean rich expectations are already baked in, or it can mean the market is willing to pay up for durability. Which side of that trade do you want to be on?
For a closer look at how the current price stacks up against earnings, valuation peers and the fair ratio, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment around AbbVie is mixed, with real risks on one side and genuine upside arguments on the other. Move quickly, review the data, and pressure test both cases for yourself through the 3 key rewards and 4 important warning signs.
Looking for more investment ideas beyond AbbVie?
Do not stop at AbbVie. Fresh opportunities often show up where fewer people are looking, and the right shortlist can save you hours of guesswork.
- Target potential upside in quality companies that may be out of favor right now by scanning a focused set of 29 high quality undervalued stocks.
- Strengthen your income stream by reviewing a curated group of 8 dividend fortresses that combine yield with business resilience.
- Dial down portfolio stress by concentrating on a 31 resilient stocks with low risk scores that prioritize financial strength and lower risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com